News Medical

Santen’s VEKTIS study demonstrates efficacy and tolerability of cyclosporine A cationic emulsion in pediatric vernal keratoconjunctivis, over 12 months

Santen EMEA is delighted to announce that the results of VEKTIS, a twelve month study in pediatric vernal keratoconjunctivitis (VKC) have been published in the American Journal of Ophthalmology. The ...
Healio

Real-world dry eye study shows long-term efficacy of cyclosporine A 0.1% cationic emulsion

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Real-world outcomes from the PERSPECTIVE study showed ...
Medscape

FDA Approves Verkazia for Vernal Keratoconjunctivitis, an Allergic Eye Disease

With the FDA's approval last week of cyclosporine ophthalmic emulsion 0.1% (Verkazia), ophthalmologists now have another option to treat their patients, both adults and children, with vernal ...
Monthly Prescribing Reference

Verkazia Now Available for Vernal Keratoconjunctivitis

Verkazia is an oil-in-water cationic emulsion that works by inhibiting T-cell activation and reducing the level of immune cells and mediators. Verkazia ® (cyclosporine ophthalmic emulsion) 0.1% is now ...
Monthly Prescribing Reference

Verkazia Approved for Vernal Keratoconjunctivitis

The approval was based on data from two randomized, multicenter, double-masked, vehicle-controlled trials that evaluated the efficacy and safety of Verkazia in patients with VKC. The Food and Drug ...